Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-06-25 18:00:06 ET · period of report 2026-06-25 · accession 0001193125-26-283139 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-25 18:00 | 2026-06-25 | KYMR | Goodman Noah | Chief Business Off | M - OptEx | $21.05 | +5,000 | 55.2K | +10% | +$105.2K |
| DMT | 2026-06-25 18:00 | 2026-06-25 | KYMR | Goodman Noah | Chief Business Off | S - Sale+OE | $114.00 | -5,000 | 50.2K | -9% | -$570.0K |
| DT | 2026-06-25 18:00 | 2026-06-25 | KYMR | Goodman Noah | Chief Business Off | M - OptEx | $0.00 | -5,000 | 90.0K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-25 | M | A | 5,000 | $21.05 | 55,195.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-06-25 | S | D | 2,500 | $109.00 | 52,695.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. |
| 3 | Common | Common Stock | 2026-06-25 | S | D | 2,500 | $119.00 | 50,195.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-06-25 | M | D | 5,000 | $0.00 | 90,000 | D | $21.05 · — to 2035-04-07 | 5,000 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. (F2) Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. |